New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

Boston, MA -- (SBWire) -- 01/25/2013 --GlobalData has released its new PharmaPoint Drug Evaluation report, "Fluad (Seasonal Influenza Vaccines) Forecast and Market Analysis". Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDermal, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

View Full Report Details and Table of Contents

Fluad is a trivalent, inactivated influenza vaccine that contains MF59 adjuvant, an oil-in-water emulsion containing squalene, polysorbate 80, and sorbitan trioleate. The virus strains present in the vaccine are grown in chicken eggs, harvested via centrifugation, inactivated with formaldehyde, and the surface antigens are purified via further centrifugation. The vaccine is indicated for immunization against seasonal influenza via intramuscular injection, and the MF59 adjuvant boosts the immune response of the recipient. Fluad was designed to improve the efficacy of influenza vaccines in elderly patients, who have waning immune systems. Fluad is marketed by Novartis in numerous European and Asian counties, including France, German, Spain, and China.

Scope

- Overview of seasonal influenza, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Fluad including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fluad for the top five countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy and Spain

Reasons to Get this Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Fluad performance
- Obtain sales forecast for Fluad from 2012 to 2022 in the US, France, Germany, Italy and Spain.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Seasonal Influenza Vaccines United States Drug Forecast and Market Analysis
- PharmaPoint: Seasonal Influenza Vaccines Italy Drug Forecast and Market Analysis
- PharmaPoint: Seasonal Influenza Vaccines Spain Drug Forecast and Market Analysis
- PharmaPoint: Seasonal Influenza Vaccines France Drug Forecast and Market Analysis
- Seasonal Influenza Vaccines Market in Top Seven Countries to 2018 - Next Generation Quadrivalent Vaccines to Dominate the Market by Offering Broader Protection via Single Dose
- Seasonal Influenza Vaccine Market in Asia-Pacific Region - Cell Culture Technology-Based Vaccines to Revolutionize the Market by Faster Production and High Initial Purity
- PharmaPoint: Seasonal Influenza Vaccines United Kingdom Drug Forecast and Market Analysis
- Influenza VLP Vaccine (Seasonal Influenza Vaccines) Forecast and Market Analysis
- PharmaPoint: Seasonal Influenza Vaccines Japan Drug Forecast and Market Analysis
- PharmaPoint: Seasonal Influenza Vaccines China Drug Forecast and Market Analysis